menu
    • menu
    [{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VDMN-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Suvretta Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Suvretta Capital","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Suvretta Capital"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"SR One | Viking Global Investors | Invus | Longitude Capital | Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series C Financing","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ SR One | Viking Global Investors | Invus | Longitude Capital | Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ SR One | Viking Global Investors | Invus | Longitude Capital | Surveyor Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Veradermics

    Menu

    Veradermics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : SR One | Viking Global Investors | Invus | Longitude Capital | Surveyor Capital

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Veradermics Boosts Hair Loss Med Hopes with $150M Funding Wave

                            Details : The Series C financing for VDPHL01 will support the development of a treatment for pattern hair loss.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 16, 2025

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : SR One | Viking Global Investors | Invus | Longitude Capital | Surveyor Capital

                            Deal Size : $150.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of VDPHL01 in Females with Androgenetic Alopecia (AGA)

                            Details : VDPHL01 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2025

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of VDPHL01 in Males With AGA

                            Details : VDPHL01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Suvretta Capital

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Veradermics Raises $75M, Starts Phase 2/3 Hair Loss Therapy Trial

                            Details : The proceeds from the financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Suvretta Capital

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of VDPHL01 in Males With AGA

                            Details : VDPHL01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of VDPHL01 in Males and Females with AGA

                            Details : VDPHL01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 30, 2024

                            Lead Product(s) : VDPHL01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Veradermics

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VDMN-21

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

                            Details : VDMN-21 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Warts.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : VDMN-21

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth